JSPR250117C7500
- 0.05
- 0.000.00%
Jasper Therapeutics Newsroom
HC Wainwright & Co. Maintains Buy on Jasper Therapeutics, Lowers Price Target to $40
Jasper Therapeutics Analyst Ratings
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $40 to $80
RBC Cuts Price Target on Jasper Therapeutics to $48 From $68, Keeps Outperform, Speculative Risk
Promising Efficacy and Safety of Jasper Therapeutics' Briquilimab Boosts Buy Rating
BMO Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $63
JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
Analysts Are Bullish on These Healthcare Stocks: Jasper Therapeutics (JSPR), Celldex (CLDX)
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $68
Analysts Conflicted on These Healthcare Names: Neurocrine (NBIX), Vertex Pharmaceuticals (VRTX) and Jasper Therapeutics (JSPR)
Jasper Therapeutics Initiated at Outperform by BMO Capital
Jasper Therapeutics Analyst Ratings
BMO Capital Initiates Jasper Therapeutics(JSPR.US) With Buy Rating, Announces Target Price $63
Stifel Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
RBC Capital Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $68
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80
A Quick Look at Today's Ratings for Jasper Therapeutics(JSPR.US), With a Forecast Between $60 to $70
Promising Outlook for Jasper Therapeutics: Buy Rating Reinforced by Advancements in Briquilimab
Oppenheimer Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $80